Cytek Biosciences, Inc. CTKB NASDAQ · Healthcare · United States
$5.76 -0.52% -$0.03
Summary
40 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $66.8M against $24.7M.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- Revenue growth is slowing: 7.1% a year over the last 3 years against 17% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 17% a year over 5 years. Over the last 3 years it grew by 7.1% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $81.2M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 1
- Sell 1
Today's price within the analysts' price targets
The average target of $4.88 is 15% below today's price. 60% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 72%
- Service 28%
By region
- UNITED STATES 47%
- EMEA 28%
- Asia Pacific 20%
- Other 4.6%
Product brings in 72% of revenue. Service grew fastest, by 61% a year.
Segments in detail